B3GALT2

Across TCGA pan-cancer cohorts, B3GALT2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B3GALT2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher B3GALT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GALT2 expression acts as an unfavorable survival marker.

HNSC, OV, and BRCA are the cancer types where B3GALT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.096	0.712	<.001	45	view →
OV	DFS	Median	All	0.122	0.542	<.001	30	view →
BRCA	OS	Median	All	0.128	0.578	.006	16	view →
CESC	DFS	Median	II,III,IV	0.146	0.705	.010	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B3GALT2–HNSC (DFS)

Open the HNSC breakdown →